Avexegen Therapeutics retains Domann to recruit a Chief Medical Officer/Medical Advisor.

Avexegen Therapeutics Inc., is an early stage development company, launched from a collaboration with Children’s Hospital Los Angeles. Their lead drug candidate, Neuregulin-4, is a naturally occurring peptide present in GI tissue as well as human breast milk, and exhibits novel protective and restorative effects on mucosal intestinal tissue. Avexegen is focusing on IND-enabling and clinical proof-of-concept studies for GI disorders, including inflammatory bowel disease (Crohn’s, ulcerative colitis) and an orphan neonate condition, necrotizing enterocolitis. Avexegen has partnered with Takeda Pharmaceuticals (non-exclusive option) and is seeking additional financing to support the next stage of development.